At first the focus of oligonucleotide drugs was on rare diseases. A lot of challenges needed to be addressed like the bioavailability and the scalability in order to address more common diseases with larger patients populations. However with the advances that have been done in the filed the past decades, the trend is changing. We observe a shift from only rare diseases for approved oligo drugs into more projects in oncology and hypertension in the phase 1 and 2 clinical trials.